29 results about "Chondrocyte cell" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses application of emetine hydrochloride in preparation of a medicine for treating osteoarthritis. A cell test shows that the chondrocyte activity can be remarkably improved by an epecinol hydrochloride alkaline solution; animal model tests show that the epecinol hydrochloride alkali solution can maintain the steady state of chondrocyte metabolism, significantly reduce the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and provides a new way for improving the osteoarthritis condition. The chemical structural formula of the emetine hydrochloride is shown in the specification.

The invention discloses a composition containing bovine bone collagen as well as a preparation method and application thereof, and belongs to the technical field of collagen application. The composition containing the bovine bone collagen is obtained by chemical crosslinking of bovine bone collagen magnesium chelate, sodium hyaluronate, chondroitin sulfate and bovine bone collagen through EDC / NHS. The composition containing bovine bone collagen is prepared from the following components in parts by weight: 5 to 10 parts of bovine bone collagen magnesium chelate, 2 to 5 parts of sodium hyaluronate, 0.5 to 2 parts of chondroitin sulfate and 20 to 30 parts of bovine bone collagen. The bovine bone collagen magnesium chelate, the sodium hyaluronate, the chondroitin sulfate and the bovine bone collagen in the composition containing the bovine bone collagen prepared by the invention have the characteristics of good biocompatibility, capability of promoting cell proliferation and differentiation into cartilage cells, and suitability for cartilage repair.

The present application relates to lipid vacuole (aka LV)-containing lipocartilage cells (aka LCs), and methods for the differentiation of human lipocartilage progenitors into LV-containing LCs. Also disclosed are methods related to purifying, labeling, maturing, and delivering of LV-containing LCs to a subject in need thereof.

It is an object of the present invention a method to obtain a cartilage cell population enriched in cartilage progenitor cells (CPCs), said method comprising culturing said cells in culture at a density between 10 and 500 cells / cm2. In a further aspect, it is here claimed a population of cartilage cells enriched in CPCs obtainable by means of said method, and their use in the treatment of chondral lesions or joint degeneration.

1. The name of the design product: bone magnetic growth instrument (MT). 2. The use of the design product: for promoting the regeneration and acceleration of chondrocytes by stimulating epiphyseal cells, and subsequent calcification into hard bone to achieve related auxiliary treatment of bone growth. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention provides a composite biological scaffold based on chondrocyte microspheres as well as a preparation method and application thereof, and relates to the technical field of biomedical materials. The composite biological scaffold based on the cartilage cell microspheres is prepared by using a process flow combining a microfluidic technology and a biological printing technology, taking the cartilage cell microspheres as a high-activity construction unit and taking light-cured hydrogel as a support carrier. In-vitro experiments show that the scaffold significantly improves cell viability, extracellular matrix deposition and chondrogenesis gene expression level, and meanwhile, the scaffold is stable in form; in-vivo research shows that the scaffold is highly similar to natural auricular cartilage in the aspects of macroscopic morphology, histological characteristics and mechanical strength. The composite biological scaffold provided by the invention not only can effectively promote the regeneration of the elastic cartilage, but also makes up the key defects of the traditional hydrogel scaffold, and provides an innovative strategy with clinical application value for auricle defect repair.

The invention discloses a preparation method of an ROS response microsphere encapsulated mitochondrial targeted nootkatone loaded Mxene multifunctional composite material, and relates to the technical field of biomedicine.The preparation method comprises the steps that carboxylated Mxene nanosheets are prepared and dissolved in dimethyl sulfoxide to obtain a product MXene-COOH-NK, then the product MXene-COOH-NK is dissolved in a 2-morpholine ethanesulfonic acid MES solution to obtain a product MXene-COOH-NK-Man, and the MXene-COOH-NK-Man is loaded on the Mxene multifunctional composite material to obtain the ROS response microsphere encapsulated mitochondrial targeted nootkatone loaded Mxene multifunctional composite material. On the basis, the ROS response microsphere encapsulated mitochondrial targeted Mxene loaded nootkatone is prepared. MXene has near-infrared photothermal conversion performance and supports light controlled drug release and local mild thermal therapy, MXene-COOH at NK can directly enrich chondrocyte mitochondria after being modified by mannosamine, expression of inflammatory factors is further inhibited, boric acid ester bonds are contained in the microspheres, and the MXene-COOH at NK can be used for preparing a drug for treating chondrocyte mitochondria, so that the MXene-COOH at NK can be used for preparing a drug for treating chondrocyte mitochondria. The nootkatone is broken under the high ROS environment condition of an OA focus, fixed-point and on-demand release of the medicine nootkatone is achieved, and whole body exposure is reduced.

This invention discloses a neutralizing nanobody targeting soluble interleukin-17 receptor D (sIL-17RD), its preparation method, and its applications. The heavy chain variable region (VHH) of this nanobody contains a heavy chain complementarity-determining region 3 (CDR-H3) that specifically binds to sIL-17RD, with a length of 10 amino acids and containing 2–6 lysine residues. This invention provides four nanobodies: CQ5, CQ13, CQ11, and CQ6, corresponding to well-defined CDR-H1, CDR-H2, and CDR-H3 sequence combinations. This nanobody can specifically bind to and neutralize the biological activity of sIL-17RD, reducing chondrocyte death, promoting proliferation, and maintaining extracellular matrix homeostasis by inhibiting the P2rx7-NLRP3 inflammasome-mediated chondrocyte pyroptosis pathway. This invention also protects the nucleic acid encoding this nanobody, the recombinant expression vector, the host cell, the pharmaceutical composition, and the preparation method. The nanobodies described can be used to prepare drugs for the prevention and treatment of inflammatory osteoarthritis and other osteoarthritis. They can inhibit synovitis, reverse cartilage and subchondral bone degeneration, and relieve pain, showing promising application prospects.

The application discloses a preparation method of ROS response microsphere encapsulated mitochondria targeted nocardicin loaded Mxene multifunctional composite material, relates to the technical field of biological medicine, and prepares carboxylated Mxene nanosheet, dissolves in dimethyl sulfoxide to obtain product MXene-COOH@NK, is dissolved in 2-morpholinoethanesulfonic acid MES solution to obtain product MXene-COOH@NK-Man, and on this basis, ROS response microsphere encapsulated mitochondria targeted Mxene loaded nocardicin is prepared. The ROS response microsphere encapsulated mitochondria targeted Mxene loaded nocardicin prepared by the application has the near-infrared light heat conversion performance of MXene to support light-controlled drug release and local mild thermotherapy, and after the modification of MXene-COOH@NK by mannose, the MXene-COOH@NK can be directly enriched with chondrocyte mitochondria, further inhibit the expression of inflammatory factors, the microsphere contains borate ester bonds, the borate ester bonds are broken under the high ROS environment condition of OA lesion, the site release of the drug nocardicin is realized, and the systemic exposure is reduced.

The invention discloses a medicine composition containing evodiamine, a medicine carrying system and application of the medicine carrying system in osteoarthritis, and belongs to the technical field of biological medicine. It is found for the first time that evodiamine can significantly inhibit cartilage cell apoptosis and promote cartilage cell proliferation; the brand new pharmacological activity provides a brand new candidate compound for the treatment of osteoarthritis. In order to further improve the curative effect, evodiamine and a medicine combination capable of intervening in macrophage polarization or adjusting the joint inflammation microenvironment are designed, the medicine combination can act on two key pathological links of cartilage repair and inflammation adjustment at the same time, and the treatment effect of osteoarthritis is greatly improved through the synergistic effect.

This invention discloses a highly sensitive chondrocyte cytoplasmic viscosity probe and its preparation method, belonging to the field of cell probe technology. The method includes: drawing a borosilicate capillary into a nanoparticle with an inner diameter of 70-490 nm; filling the tube lumen with an aminosilane solution and incubating at room temperature to achieve amino functionalization modification; and finally injecting PBS buffer to obtain the probe. Amino modification significantly enhances the charge density of the nanoparticle's inner wall. When the inner diameter of the nanoparticle tip is reduced to 120 nm, the spatial confinement effect significantly enhances the regulatory effect of the enhanced surface charge on ion transport, strengthens the electric double layer effect and electroosmotic effect, and makes the ion current highly sensitive to changes in solution viscosity, thereby greatly improving the probe's response sensitivity to small viscosity fluctuations. The preparation method of this invention is simple and efficient, and the resulting probe has a fast response speed, enabling real-time dynamic monitoring of chondrocyte cytoplasmic viscosity, providing a highly sensitive tool for early warning and mechanism research of diseases such as osteoarthritis.

This application relates to stem cell biology and regenerative medicine. Disclosed herein are agents and methods for converting non-chondrocyte cells to chondrocytes or chondrogenic ceils, related cells, related compositions, related products, and related uses.

The invention relates to the technical field of traditional Chinese medicines, in particular to a medicinal and edible traditional Chinese medicine compound GCNY-0318 for treating osteoarthritis and a preparation method of tablets of the medicinal and edible traditional Chinese medicine compound GCNY-0318. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 10-30 parts of liquorice, 5-15 parts of ginseng, 3-10 parts of dried ginger, 10-20 parts of dandelion, 5-15 parts of momordica grosvenori, 10-20 parts of radix polygonati officinalis and 5-15 parts of Chinese dates. The invention provides a therapy for delaying senescence of cartilage cells of osteoarthritis patients and regulating inflammation, the activation of a YWHAZ / PI3K / AKT signal channel is inhibited, and the integrity of articular cartilage of osteoarthritis is protected, so that the pathological progress of osteoarthritis is slowed down.

The invention relates to a filler composition for cartilage cell differentiation capacity and collagen activity and a preparation method thereof. The composition comprises a mixture of PLGA microparticles and HA and PDRN microparticles, and can be usefully used as a filler composition by stably inducing cell adsorption, improving collagen production, activating cartilage cell regeneration, and verifying tissue repair effects.

Provided herein are systems for regulating gene expression, methods for their use, and cells, such as cells engineered for the purpose of differentiating chondroprogenitor cells.

The invention relates to the technical field of medicine, and discloses hyaluronic acid-silk fibroin hydrogel injected into a bone joint cavity and a preparation method of the hyaluronic acid-silk fibroin hydrogel. The gel particles contain hyaluronic acid or salt thereof, silk fibroin and a cross-linking agent; the cross-linking agent is BDDE; the molecular weight of the silk fibroin is 2.5-100 thousand Daltons; the preparation method comprises the following steps: a, dissolving a certain amount of hyaluronic acid or salt thereof and silk fibroin powder in an alkaline solution, uniformly stirring, and carrying out defoaming treatment; b, adding a proper amount of cross-linking agent BDDE into the solution defoamed in the step a to form a mixed solution, carrying out cross-linking, and then dialyzing; c, the gel obtained after dialysis in the step b is sieved through a 40-100-mesh sieve to be granulated, and gel particles are obtained; and d, adding a proper amount of aqueous medium into the gel particles in the step c for resuspension to obtain the hyaluronic acid-silk fibroin hydrogel. The hydrogel disclosed by the invention has excellent mechanical properties, viscoelasticity and abundant porous structures, is remarkable in anti-inflammatory effect, can promote the growth of cartilage cells, is used for intraarticular injection and treatment of osteoarticular related diseases, and has a better industrial production prospect.

The invention belongs to the technical field of biological medicines, and particularly relates to application of purine deoxynucleotide in preparation of a medicine for treating osteoarthritis, the purine deoxynucleotide comprises any one of deoxyguanosine monophosphate and deoxyadenosine monophosphate, the molecular formula of the deoxyguanosine monophosphate is C10H12N5Na2O7P, and the molecular formula of the deoxyadenosine monophosphate is C10H12N5Na2O7P. The molecular formula of the deoxyadenosine monophosphate is C10H14N5O6P. A research result shows that the purine deoxynucleotide has an inhibiting effect on the activity of cartilage cells; animal model tests show that the purine deoxynucleotide can significantly reduce the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and a new way is provided for improvement of osteoarthritis conditions.

A chitosan temperature-sensitive gel composition for treating osteoarthritis and a preparation method therefor. The composition comprises 0.5%-5% of a chitosan temperature-sensitive gel and 106-107 / mL of stem cells. Mixing mesenchymal stem cells and the chitosan temperature-sensitive gel and then injecting same into articular cavities can exert the joint lubricating effect of the chitosan gel itself, and the mesenchymal stem cells can secrete a large number of inflammation inhibitory cytokines, and can also promote cartilage cell regeneration, thereby effectively treating osteoarthritis.

This invention discloses a CH@SHP099-NPs composite hydrogel, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the technical challenge of achieving long-term, safe, and precise metabolic intervention with SHP2, this invention constructs a hydrogel system composed of chondroitin sulfate and hyaluronic acid. This system can retain SHP099-loaded nanoparticles within the joint cavity, forming a long-acting intrasynovial drug library, thereby continuously inhibiting the SHP2-AMPK signaling axis. The CH@SHP099-NPs composite hydrogel prepared in this invention can effectively reprogram the metabolic state of macrophages, reduce glycolysis flux, restore synovial immune metabolic homeostasis, and significantly improve synovial inflammation, chondrocyte activity, and cartilage structural integrity in vivo. This invention proposes a mechanism-guided local delivery metabolic intervention strategy, which is expected to provide a new interventional approach for the treatment of osteoarthritis.

This invention relates to an electroactive casein bio-ink, its preparation method, and its applications, belonging to the field of biomedical materials technology. The ink uses quaternized methacrylamide casein (QCMA) as its core component, combined with a photoinitiator and chondrocytes. The preparation method involves first introducing quaternization into the casein to introduce cationic groups, then grafting photosensitive double bonds via methacrylation, purifying the resulting QCMA powder, and finally compounding it with a photoinitiator and cells to form the ink. This bio-ink possesses both high transparency and rapid photocuring properties, making it suitable for high-precision DLP printing. The constructed hydrogel exhibits intrinsic ionic conductivity, enabling the reconstruction of the electrophysiological microenvironment of damaged tissues and acting as an "electric bridge." Simultaneously, its quaternary ammonium groups endow the material with broad-spectrum antibacterial capabilities and promote cell adhesion and matrix deposition. The material of this invention is applicable to tissue regeneration fields such as cartilage defect repair.

The invention discloses application of miR-130b-5p in preparation of a medicine for treating osteoarthritis, a sustained release system and a preparation method, and belongs to the technical field of medicines, and the sustained release system is ZIF-8 (at) miR-130b-5p constructed by ZIF-8 loaded miR-130b-5p. The miR-130b-5p provided by the invention can be used for remarkably relieving cartilage cell injury in an inflammation environment and improving a local inflammation state. In an OA mouse model, the ZIF-8 (at) miR-130b-5p sustained-release system disclosed by the invention can be used for remarkably improving the inflammatory response and cartilage injury of a joint focus area and remarkably improving the motor function.

The invention relates to the technical field of biological medicines, and particularly discloses application of guanosine monophosphate in preparation of a medicine for treating osteoarthritis. Cell tests show that the guanosine monophosphate solution has an inhibition effect on cartilage cell activity; animal model tests show that the guanosine monophosphate normal saline solution can remarkably relieve the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and a new way is provided for improvement of osteoarthritis conditions. The chemical structural formula of guanosine monophosphate is shown in the specification.

The present application belongs to the field of biomedical technology, and relates to a berberine / chondrocyte / injectable hydrogel biomimetic material, a preparation method and application thereof. The present application combines phosphoric acid modified methylacrylate chitosan injectable hydrogel (scaffold material), chondrocyte (seed cell) and berberine (bioactive substance) into one to form a berberine / chondrocyte / injectable hydrogel biomimetic cartilage scaffold material. The material can realize long-time effect of berberine on chondrocyte, is prepared into a cartilage scaffold, can act on residual chondrocyte and new chondrocyte around the cartilage scaffold, realizes regeneration and repair of cartilage tissue on the basis of climbing material provided by the hydrogel, and has a "1+1+1>3" effect, thereby providing a new strategy for cartilage defect treatment.

The application provides a compound bone health composition containing astragalus polysaccharide and polypeptide and a preparation method and application thereof, and belongs to the technical field of biological medicine. The composition is prepared by compounding astragalus polysaccharide and collagen polypeptide, the astragalus polysaccharide is prepared by high-pressure pulse electric field combined with low eutectic solvent ultrasonic extraction, and the collagen polypeptide is prepared by compound microbial fermentation, step-by-step enzymolysis and purification. The astragalus polysaccharide and the collagen polypeptide have a significant synergistic effect, the astragalus polysaccharide has anti-inflammatory and antioxidant effects and optimizes the repair microenvironment, and the collagen polypeptide provides repair raw materials and promotes tissue regeneration. The composition can efficiently promote the repair of joint movement injury, can improve the chondrocyte activity, can remove active oxygen and can inhibit the secretion of inflammatory factors. Cell experiments and zebra fish animal experiments show that the composition has excellent repair effect, the bone health product prepared based on the composition also has good repair performance, and has important clinical value and market prospect.

The application relates to the field of biomedical technology, and particularly discloses application of an exosome overexpressing CAP and LGR5 genes in preparation of a drug for treating cartilage inflammation. The exosome overexpressing the CAP and LGR5 genes has both targeting property and cartilage protection function, the exosome can be more phagocytosed by cartilage cells, is targeted to the cartilage cells, can improve the levels of a cartilage generation gene Col2a1 and a cartilage development regulating gene Sox9, can reduce the level of a cartilage degradation gene Mmp13, can relieve cartilage abrasion of osteoarthritis mice, and can protect knee joints, so that the exosome can promote cartilage generation, relieve cartilage aging and reduce cartilage degradation under a complex inflammation environment. Further, the application provides a mesenchymal stem cell exosome overexpressing CAP / LGR5, provides a new technical scheme for targeted treatment based on stem cell engineering, and has a wide application prospect.

The present disclosure provides compositions and methods for treating osteoarthritis, such as osteoarthritis in a subject. The method comprises blocking the opening of the Cx43 hemichannel in cartilage cells by, for example, using a composition comprising an anticonnexin 43 antibody.

The invention discloses a recombinant collagen modified cationic liposome as well as a preparation method and application thereof, and the recombinant collagen modified cationic liposome comprises a cationic liposome and recombinant III type humanized collagen modified on the surface of the cationic liposome, the cationic liposome and the recombinant III type humanized collagen form nano-particles with a core-shell structure. The recombinant III-type humanized collagen can be used for modifying the cationic liposome, so that the technical problem that the existing cationic liposome is high in toxicity is solved, the biocompatibility of the cationic liposome is improved, and the functions of promoting cartilage cell proliferation, resisting inflammation and the like are achieved.